TWiV 988: Clinical update with Dr. Daniel Griffin

This Week in Virology

Vincent Racaniello

Vincent, Microbe, Medicine, Microbiology, Racaniello, Infection, Virus, Virology, Pathogen, Infectious, Twiv, Science & Medicine

4.8 • 2.2K Ratings

🗓️ 4 March 2023

⏱️ 41 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In his weekly clinical update Dr. Griffin discusses FDA authorizing the first over-the-counter at-home test to detect both influenza and COVID-19, monoclonal antibody for the prevention of respiratory syncytial virus infection in infants and children, epidemiologic characteristics of SARS-CoV-2 recombinant variant XBB.1.5, COVID-19 vaccines vs pediatric hospitalization, maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life, immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children, fatal fulminant cerebral edema in six children with SARS-CoV-2 Omicron BA.2 infection in Taiwan, certifying deaths due to COVID-19, efficacy of first dose of COVID-19 vaccine vs no vaccination on symptoms of patients with long COVID, and the effect of COVID-19 vaccination on long COVID. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode FDA authorizes over-the-counter at-home test to detect both Influenza and COVID-19 (FDA) Monoclonal antibody for the prevention of RSV in infants and children (JAMA) Epidemiologic characteristics of SARS-CoV-2 variant XBB.1.5 (CDC) COVID-19 vaccines vs pediatric hospitalization (Cell) Maternal SARS-CoV-2 vaccination and infant protection during the first six months of life (Nature) Immunoglobulin, glucocorticoid, or combination therapy for MIS in children (The Lancet) Fatal Fulminant Cerebral Edema in children with SARS-CoV-2 Omicron BA.2 infection (JPID) Certifying deaths due to COVID-19 (CDC) Efficacy of first dose of COVID-19 vaccine vs no vaccination on patients with Long COVID (BMJ) Effect of COVID-19 vaccination on long COVID (BMJ) Contribute to our ASTMH fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 988 Don't crush Paxlovid (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]

Transcript

Click on a timestamp to play from that location

0:00.0	This week in virology, the podcast about viruses, the kind that make you sick.
0:10.4	From microbe TV, this is TWIV, this week in virology, episode 988 recorded on March 2nd, 2023.
0:20.6	I'm Vincent Racken-Ello, and you're listening to the podcast all about viruses. Joining me today from
0:27.2	New York, Daniel Griffin. Hello, everyone. So Daniel, are you upset at the possibility that Nova
0:34.8	Vax might go out of business? I am actually. Yeah, I mean, I'm hearing that their stock has fallen
0:41.6	off a cliff, right? They are concerned that going forward, they might not be able to survive.
0:47.7	I'm not so much concerned about the company as I am about the product. It is amazing to me,
0:53.9	how few people have gone ahead with the Nova Vax vaccine. Everyone complains,
0:58.6	oh, the mRNA technology, and this and that. Well, here is a protein-based vaccine, this is the same
1:05.9	thing. Shingles, no one box, no one thinks they're getting a shingle shot, is any sort of odd.
1:12.3	But yeah, I don't think we can let this happen. I don't see the product going away,
1:16.8	but it is a little troubling. And actually, as we get into today, I talk about another company that
1:21.8	might be going bankrupt. Well, it seems to me that part of the issue was the adjuvant they used,
1:26.9	which was difficult to obtain, I understand, and that's too bad. But I do think it offers an
1:33.1	alternative for people who would like to try something else, right? And even for people that can't
1:38.4	tolerate, and if we are going to be talking about boosting on a regular basis, certain people
1:43.1	are going to want another option because they have a peg allergy or some other issue. So yeah,
1:48.4	we do need more options. I don't like the idea of there's only one type of vaccine, and that's it.
1:55.2	And last week, you talked about RS virus vaccines, and one of them was a protein-based vaccine.
2:01.2	Yeah, it is interesting. Everyone sort of had this idea like, oh my gosh, mRNA vaccines,
2:05.8	that's the future. It's really just a way of showing the protein to our immune system and
2:11.5	getting our immune system to learn. I'm not sure that it is essential that every vaccine in the
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vincent Racaniello, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vincent Racaniello and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.